Westhampton Capital LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, HoldingsChannel reports. The institutional investor purchased 9,110 shares of the biopharmaceutical company’s stock, valued at approximately $615,000.
A number of other large investors have also modified their holdings of GILD. Advisors Preferred LLC acquired a new stake in Gilead Sciences in the 2nd quarter worth about $26,000. Creative Financial Designs Inc. ADV boosted its stake in Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 165 shares during the last quarter. Trustcore Financial Services LLC acquired a new stake in Gilead Sciences in the 1st quarter worth about $34,000. Weaver Consulting Group acquired a new stake in Gilead Sciences in the 1st quarter worth about $34,000. Finally, Legacy Advisors LLC acquired a new stake in Gilead Sciences in the 2nd quarter worth about $37,000. 78.78% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have issued reports on GILD shares. Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $68.00 to $88.00 in a research note on Monday, July 15th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research note on Wednesday, July 31st. Raymond James lifted their price objective on Gilead Sciences from $83.00 to $86.00 and gave the company a “strong-buy” rating in a research note on Wednesday, July 31st. Oppenheimer set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Friday, July 12th. Finally, Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $82.29.
Shares of NASDAQ:GILD traded down $1.30 during mid-day trading on Friday, hitting $62.92. 417,667 shares of the company traded hands, compared to its average volume of 6,097,710. The firm has a market cap of $80.60 billion, a P/E ratio of 10.22, a PEG ratio of 3.01 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $79.61. The firm’s 50 day simple moving average is $65.65 and its 200 day simple moving average is $65.77.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.68 by $0.14. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The company’s revenue was down 2.8% on a year-over-year basis. During the same period last year, the business posted $1.91 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 6.65 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, September 12th. This represents a $2.52 annualized dividend and a dividend yield of 4.01%. Gilead Sciences’s payout ratio is currently 40.98%.
In related news, EVP Brett A. Pletcher sold 7,200 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the sale, the executive vice president now directly owns 34,398 shares in the company, valued at approximately $2,238,277.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total value of $399,850.00. Following the sale, the executive vice president now owns 27,198 shares in the company, valued at $1,869,862.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,624 shares of company stock worth $907,479. Company insiders own 0.20% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: What is the Russell 2000 Index?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.